Terms: = Skin cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874
43 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Predictors for delayed awakening in adult glioma patients receiving awake craniotomy under monitored anesthesia care.
Lin HT; Lin CM; Wu YY; Chang WH; Wei KC; Chen YC; Chen PY; Liu FC; Chen KT
J Neurooncol; 2023 Nov; 165(2):361-372. PubMed ID: 37917280
[TBL] [Abstract] [Full Text] [Related]
3. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract] [Full Text] [Related]
4. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract] [Full Text] [Related]
5. The first-in-human phase I study of a brain-penetrant mutant idh1 inhibitor DS-1001 in patients with recurrent or progressive idh1-mutant gliomas.
Natsume A; Arakawa Y; Narita Y; Sugiyama K; Hata N; Muragaki Y; Shinojima N; Kumabe T; Saito R; Motomura K; Mineharu Y; Miyakita Y; Yamasaki F; Matsushita Y; Ichimura K; Ito K; Tachibana M; Kakurai Y; Okamoto N; Asahi T; Nishijima S; Yamaguchi T; Tsubouchi H; Nakamura H; Nishikawa R
Neuro Oncol; 2023 Feb; 25(2):326-336. PubMed ID: 35722822
[TBL] [Abstract] [Full Text] [Related]
6. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for cancers: A Bibliometric Analysis.
Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
Front Immunol; 2022; 13():862084. PubMed ID: 35493449
[TBL] [Abstract] [Full Text] [Related]
7. idh1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia.
Dunn-Valadez S; Bathini S; Elston C; Rangaraju S; Stasi AD; Worth S; Morlote D; Harada S; Vachhani P
Cancer Treat Res Commun; 2022; 31():100560. PubMed ID: 35460975
[TBL] [Abstract] [Full Text] [Related]
8. An Atypical Deep Penetrating Nevus With Mutations in Beta Catenin , BRAFV600E , and idh1R132C in an 8-Year-Old Boy.
Ireland AM; Wood BA; Whitfield J; Amanuel B; Harvey NT; Mesbah Ardakani N
Am J Dermatopathol; 2022 Aug; 44(8):607-610. PubMed ID: 35385855
[TBL] [Abstract] [Full Text] [Related]
9. Tumour treating fields in glioblastoma: is the treatment tolerable, effective, and practical in UK patients?
Olubajo F; Thorpe A; Davis C; Sinha R; Crofton A; Mills SJ; Williams M; Jenkinson MD; Price SJ; Watts C; Brodbelt AR
Br J Neurosurg; 2022 Dec; 36(6):770-776. PubMed ID: 35200077
[TBL] [Abstract] [Full Text] [Related]
10. Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.
Lim-Fat MJ; Song KW; Iorgulescu JB; Andersen BM; Forst DA; Jordan JT; Gerstner ER; Reardon DA; Wen PY; Arrillaga-Romany I
J Neurooncol; 2021 May; 152(3):515-522. PubMed ID: 33646525
[TBL] [Abstract] [Full Text] [Related]
11. Glioblastoma and malignant melanoma: Serendipitous or anticipated association?
Yang K; Stein TD; Huber BR; Sartor EA; Rachlin JR; Mahalingam M
Neuropathology; 2021 Feb; 41(1):65-71. PubMed ID: 33103282
[TBL] [Abstract] [Full Text] [Related]
12. Hsa-miR-27a-3p and epidermal growth factor receptor expression analysis in glioblastoma FFPE samples.
Salmani T; Ghaderian SMH; Hajiesmaeili M; Rezaeimirghaed O; Hoseini MS; Rakhshan A; Nasiri MJ; Ghaedi H; Akbarzadeh R
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e185-e190. PubMed ID: 33029912
[TBL] [Abstract] [Full Text] [Related]
13. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma.
Herrera-Rios D; Li G; Khan D; Tsiampali J; Nickel AC; Aretz P; Hewera M; Suwala AK; Jiang T; Steiger HJ; Kamp MA; Muhammad S; Hänggi D; Maciaczyk J; Zhang W; Kahlert UD
Sci Rep; 2020 Oct; 10(1):16218. PubMed ID: 33004830
[TBL] [Abstract] [Full Text] [Related]
14. Cutaneous Melanocytic Tumors With Concomitant NRASQ61R and idh1R132C Mutations: A Report of 6 Cases.
Macagno N; Pissaloux D; Etchevers H; Haddad V; Vergier B; Sierra-Fortuny S; Tirode F; de la Fouchardière A
Am J Surg Pathol; 2020 Oct; 44(10):1398-1405. PubMed ID: 32732488
[TBL] [Abstract] [Full Text] [Related]
15. Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Olbryt M; Pigłowski W; Rajczykowski M; Pfeifer A; Student S; Fiszer-Kierzkowska A
Target Oncol; 2020 Feb; 15(1):101-113. PubMed ID: 31980996
[TBL] [Abstract] [Full Text] [Related]
16. Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
Donati M; Zelano G; Coppola R; Cinelli E; Verri M; Persichetti P; Perrella E; Devirgiliis V; Calvieri S; Crescenzi A; Panasiti V
Ital J Dermatol Venerol; 2021 Oct; 156(5):593-598. PubMed ID: 31804055
[TBL] [Abstract] [Full Text] [Related]
17. The cancer driver genes idh1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
18. An insight into the molecular genetics of a uveal melanoma patient cohort.
Kennedy S; Rice M; Toomey S; Horgan N; Hennessey BT; Larkin A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1861-1868. PubMed ID: 30008023
[TBL] [Abstract] [Full Text] [Related]
19. Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.
Linos K; Tafe LJ
Histopathology; 2018 Dec; 73(6):963-968. PubMed ID: 30003571
[TBL] [Abstract] [Full Text] [Related]
20. Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.
Kubasch AS; Wehner R; Bazzurri S; Tunger A; Stasik S; Garzarolli M; Meinel J; Baretton G; Meier F; Thiede C; Schmitz M; Platzbecker U
Blood Adv; 2018 Jun; 2(11):1187-1190. PubMed ID: 29844203
[TBL] [Abstract] [Full Text] [Related]
[Next]
